影像组学在肝癌合并门静脉癌栓中的研究进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v6i5.10097
Abstract
原发性肝癌是一种常见的恶性肿瘤,其中门静脉癌栓(portal vein tumor thrombus,PVTT)是晚期原发性肝癌常见的并发症之一,也是提示肝癌治疗预后差的因素之一。肝癌患者一旦出现PVTT,病情发展迅速,短时间内即可发生肝内外转移、门静脉高压、黄疸、腹水等一系列严重的症状。随着医学影像的数字化及信息量的快速增长,传统定性的医学图像分析方法已无法满足日益增长的需求和不断提高的要求。影像组学(Radiomics)是一种被誉为可以突破和革新传统影像图像处理和数据分析的方法,它作为一种新兴技术,可从图像中提取人类肉眼难以观察及分辨的大量参数,并通过多种算法将图像数据转化为高维和可挖掘的数据,故能对疾病的异质性进行全面量化分析。本文就影像组学在原发性肝细胞癌合并PVTT中的研究进展作一综述。
Keywords
原发性肝癌；门静脉癌栓；影像组学
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Ferlay J,Colombet M,Soerjomataram I,et al. Estimating the global cancer incidence and mortality in 2018:GLOBOCAN sources and methods[J].Int J Cancer,2019,144(8):1941-1953.
[2] Lu XY,Xi T,Lau WY,et al.Pathobiological features of small hepatocellular carcinoma:correlation between tumor size and biological behavior[J].J Cancer Res Clin Oncol,2011,137(4):567-575.
[3] Lambin P,Rios-Velazquez E,Leijenaar R,etal.Radiomics: Extracting more information from medical images using ad-vaneed feature analysis_]],European Journal of Cancer(Or -ford,England:1990),2012,48(4):441-446.
[4] 隋赫,莫展豪,孙旭,等,影像组学的图像分析及模型构建[J].中国医疗设备,2019,34(4):25-28,37.
[5] LiuZY, Wang S,Dong D,etal.The applications of radiomics in precision diagnosis and treatment of oncology: opportuni ties andchallenges[J].Theranostics,2019,9(5):1303-22.
[6] Zhu M, Li SJ, Kuang Y, et al. Artificial intelligence in the radiomic analysis of glioblastomas: a review, taxonomy, and perspective[J].Front Oncol,2022,12:924245.
[7] Mayerhoefer ME, Materka A, Langs G, et al. Introduction to radiomics[J].J Nucl Med,2020,61(4):488-95.
[8] Castaldo A, De Lucia DR, Pontillo G, et al. State of the art in artificial intelligence and radiomics in hepatocellular carcinoma[J].Diagnostics,2021,11(7):1194.
[9] Filippiadis D K, Velonakis G, Kelekis A, et al. The role of percutaneous ablation in the management of colorectal cancer liver metastatic disease[J].Diagnostics,2021,11(2): 308.
[10] Ren S, Zhang JJ, Chen JY, et al. Evaluation of texture analysis for the differential diagnosis of mass-forming panc reatitis from pancreatic ductal adenocarcinoma on contrast -enhanced CT images[J].Front Oncol,2019,9:1171.
[11] European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Management of hepatocellu lar carcinoma[J].J Hepatol,2018,69(1):182-236.
[12] National Comprehensive Cancer Network.(NCCN)Clinical Practice Guidelines in Oncology.Hepatobiliary Cancer. Version 2[S/OL].2021.https://www.nccn.org/.
[13] Kokudo N,Takemura N,Hasegawa K,etal.Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH- HCC guidelines) 2019 update[J]. Hepatol Res,2019,49(10):1109-1113.
[14] 中华医学会数字医学分会,中国医师协会肝癌专业委员会,中国医师协会精准医学专业委员会,等.原发性肝癌三维可视化技术操作及诊疗规范(2020版)[J].中国实用外科杂志,2020,40(9):991-1011.
[15] KumadaK,OzawaK,OkamotoR,etal.Hepatic resection for advanced hepatocellular carcinoma with removal of portal vein tumor thrombi[J].Surgery,1990,108(5):821-827.
[16] 中国医师协会肝癌专业委员会.肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版)[J].中国实用外科杂志,2019,39(1):46-52.
[17] RyonEL,Kronenfeld JP,Lee RM,etal.Surgical managem ent of hepatocellular carcinoma patients with portal veinthrombosis: The United States safety net and academic center collaborative analysis[J].J Surg Oncol,2021,123(2):407-415.
[18] LIU P H, HUO T I, MIKSAD R A. Hepatocellular carcinoma with portal vein tumor involvement:best management strategies [J].Semin Liver Dis,2018,38(3):242-251.
[19] OMATA M, CHENG A L, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocel lular carcinoma:a 2017 update[J].Hepatol Int,2017,11(4):317-370.
[20] 刘颖,魏小琴,王芳,等.基于CT影像组学预测肝细胞癌TACE术后疗效[J].临床放射学杂志,2023,42(2):311-316.
[21] Kim J, Choi S J, Lee S H,et al. Predicting survival usingpretreatment CT for patients with hepatocellular carcin omatreated with transarterial chemoembolization:Comparison ofmodels using radiomics[J].American Journal of Roentgenology,2018,211(5):1026-1034.
[22] Meng XP, Wang YC, JuS H, et al, Radiomics analysis onmultiphase contrast-enhanced CT:A survival prediction tool in patients with hepatocellular carcinoma undergoing transa rterial chemoembolization[J]. Frontiers in Oncology, 2020,10: 1196.
[23] Lill,Kan XF,Zhao YJ,etal.Radiomics Signature:Apotential biomarker for the prediction of survival in AdvancecHepatoce llular Carcinoma.InternationalouralofMedical Sciences,202l,18(11):2276-2284.
[24] Chen M, Cao J,Hu J,et al. Clinicalradiomic analysis for pretreatment prediction of objective response to first tran sarterialchemoembolization in hepatocellular carcinoma[J].Liver Cancer,2021,10(1):38-51.
[25] Jin Z,Chen L,Zhong B,et al. Machine-Learning analysis of con-trast-enhanced computed tomography radiomics predi cts patientswith hepatocellular carcinoma who are unsuitable for initialtransarterial chemoembolization monotherapy:a multicenterstudy[j].Transl Oncol,2021,14(4):101034.
[26] Qi X,Liu L,Wang D,et al. Hepatic resection alone versus in combination with pre-and post-operative transarterial chemoem-bolization for the treatment of hepatocellular carcinoma:a systematic review and metaanalysis[J]. Oncotarget, 2015,6(34):36838-36859.
[27] 龙颖琳,许尔蛟,郑荣琴.融合成像技术在肝癌消融中的应用进展[J].中华医学超声杂志(电子版),2017,14(01):19-22.
[28] Li N,Wan X,Zhang H,etal.Tumor and peritumor radiomies analysis based on contrastenhanced CT for predicting early andlate recurrence of hepatocellular carcinoma after liver resection[J].BMC Cancer,2022,22(1):664.
[29] Gao W,Wang W,Song D,etal,A predictive model integrat ingdeep and radiomics features based on gadobenate dimegl umineenhanced mri for postoperative early recurrence of hepatocellularcarcinoma[J],RadiolMed(Torino),2022,127(3):259-271.
[30] 李嘉颖,丁洪蕾,张华妮,等.原发性肝癌DWI影像组学特征与中医证型的相关性研究[J].中国中西医结合影像学杂志,2022,20(2):146-50.
[2] Lu XY,Xi T,Lau WY,et al.Pathobiological features of small hepatocellular carcinoma:correlation between tumor size and biological behavior[J].J Cancer Res Clin Oncol,2011,137(4):567-575.
[3] Lambin P,Rios-Velazquez E,Leijenaar R,etal.Radiomics: Extracting more information from medical images using ad-vaneed feature analysis_]],European Journal of Cancer(Or -ford,England:1990),2012,48(4):441-446.
[4] 隋赫,莫展豪,孙旭,等,影像组学的图像分析及模型构建[J].中国医疗设备,2019,34(4):25-28,37.
[5] LiuZY, Wang S,Dong D,etal.The applications of radiomics in precision diagnosis and treatment of oncology: opportuni ties andchallenges[J].Theranostics,2019,9(5):1303-22.
[6] Zhu M, Li SJ, Kuang Y, et al. Artificial intelligence in the radiomic analysis of glioblastomas: a review, taxonomy, and perspective[J].Front Oncol,2022,12:924245.
[7] Mayerhoefer ME, Materka A, Langs G, et al. Introduction to radiomics[J].J Nucl Med,2020,61(4):488-95.
[8] Castaldo A, De Lucia DR, Pontillo G, et al. State of the art in artificial intelligence and radiomics in hepatocellular carcinoma[J].Diagnostics,2021,11(7):1194.
[9] Filippiadis D K, Velonakis G, Kelekis A, et al. The role of percutaneous ablation in the management of colorectal cancer liver metastatic disease[J].Diagnostics,2021,11(2): 308.
[10] Ren S, Zhang JJ, Chen JY, et al. Evaluation of texture analysis for the differential diagnosis of mass-forming panc reatitis from pancreatic ductal adenocarcinoma on contrast -enhanced CT images[J].Front Oncol,2019,9:1171.
[11] European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Management of hepatocellu lar carcinoma[J].J Hepatol,2018,69(1):182-236.
[12] National Comprehensive Cancer Network.(NCCN)Clinical Practice Guidelines in Oncology.Hepatobiliary Cancer. Version 2[S/OL].2021.https://www.nccn.org/.
[13] Kokudo N,Takemura N,Hasegawa K,etal.Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH- HCC guidelines) 2019 update[J]. Hepatol Res,2019,49(10):1109-1113.
[14] 中华医学会数字医学分会,中国医师协会肝癌专业委员会,中国医师协会精准医学专业委员会,等.原发性肝癌三维可视化技术操作及诊疗规范(2020版)[J].中国实用外科杂志,2020,40(9):991-1011.
[15] KumadaK,OzawaK,OkamotoR,etal.Hepatic resection for advanced hepatocellular carcinoma with removal of portal vein tumor thrombi[J].Surgery,1990,108(5):821-827.
[16] 中国医师协会肝癌专业委员会.肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版)[J].中国实用外科杂志,2019,39(1):46-52.
[17] RyonEL,Kronenfeld JP,Lee RM,etal.Surgical managem ent of hepatocellular carcinoma patients with portal veinthrombosis: The United States safety net and academic center collaborative analysis[J].J Surg Oncol,2021,123(2):407-415.
[18] LIU P H, HUO T I, MIKSAD R A. Hepatocellular carcinoma with portal vein tumor involvement:best management strategies [J].Semin Liver Dis,2018,38(3):242-251.
[19] OMATA M, CHENG A L, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocel lular carcinoma:a 2017 update[J].Hepatol Int,2017,11(4):317-370.
[20] 刘颖,魏小琴,王芳,等.基于CT影像组学预测肝细胞癌TACE术后疗效[J].临床放射学杂志,2023,42(2):311-316.
[21] Kim J, Choi S J, Lee S H,et al. Predicting survival usingpretreatment CT for patients with hepatocellular carcin omatreated with transarterial chemoembolization:Comparison ofmodels using radiomics[J].American Journal of Roentgenology,2018,211(5):1026-1034.
[22] Meng XP, Wang YC, JuS H, et al, Radiomics analysis onmultiphase contrast-enhanced CT:A survival prediction tool in patients with hepatocellular carcinoma undergoing transa rterial chemoembolization[J]. Frontiers in Oncology, 2020,10: 1196.
[23] Lill,Kan XF,Zhao YJ,etal.Radiomics Signature:Apotential biomarker for the prediction of survival in AdvancecHepatoce llular Carcinoma.InternationalouralofMedical Sciences,202l,18(11):2276-2284.
[24] Chen M, Cao J,Hu J,et al. Clinicalradiomic analysis for pretreatment prediction of objective response to first tran sarterialchemoembolization in hepatocellular carcinoma[J].Liver Cancer,2021,10(1):38-51.
[25] Jin Z,Chen L,Zhong B,et al. Machine-Learning analysis of con-trast-enhanced computed tomography radiomics predi cts patientswith hepatocellular carcinoma who are unsuitable for initialtransarterial chemoembolization monotherapy:a multicenterstudy[j].Transl Oncol,2021,14(4):101034.
[26] Qi X,Liu L,Wang D,et al. Hepatic resection alone versus in combination with pre-and post-operative transarterial chemoem-bolization for the treatment of hepatocellular carcinoma:a systematic review and metaanalysis[J]. Oncotarget, 2015,6(34):36838-36859.
[27] 龙颖琳,许尔蛟,郑荣琴.融合成像技术在肝癌消融中的应用进展[J].中华医学超声杂志(电子版),2017,14(01):19-22.
[28] Li N,Wan X,Zhang H,etal.Tumor and peritumor radiomies analysis based on contrastenhanced CT for predicting early andlate recurrence of hepatocellular carcinoma after liver resection[J].BMC Cancer,2022,22(1):664.
[29] Gao W,Wang W,Song D,etal,A predictive model integrat ingdeep and radiomics features based on gadobenate dimegl umineenhanced mri for postoperative early recurrence of hepatocellularcarcinoma[J],RadiolMed(Torino),2022,127(3):259-271.
[30] 李嘉颖,丁洪蕾,张华妮,等.原发性肝癌DWI影像组学特征与中医证型的相关性研究[J].中国中西医结合影像学杂志,2022,20(2):146-50.
Copyright © 2024 王天涛, 王志鑫
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
